Extracted from this filing and checked against the source text.
Restructurings & Charges
SEC 8-K Item 2.05/2.06
confidence 0.95
STANDARD BIOTOOLS INC. announced a restructuring with charges of Reduction-in-force of approximately 10% of total workforce, including elimination of certain senior management positions, with expected expenses of $10 million affecting total workforce (approximately 10% of its total workforce).
- Type
- restructuring
- Charge
- Reduction-in-force of approximately 10% of total workforce, including elimination of certain senior management positions, with expected expenses of $10 million
- Affected area
- total workforce
- Headcount
- approximately 10% of its total workforce
Exact text from the filing
On April 25, 2024, Standard BioTools Inc. (the “Company”) announced a reduction-in-force of approximately 10% of its total workforce, including the elimination of certain senior management positions following the closing of the Company’s merger with SomaLogic, Inc., as part of an operational restructuring plan.
View on SEC.gov
Restructurings & Charges
SEC 8-K Item 2.05/2.06
confidence 0.9
STANDARD BIOTOOLS INC. announced a restructuring with charges of Streamlined Operational Expenditures including closure of the Company's R&D facility in San Diego, reductions in SG&A expenses, and savings related to a more pr affecting R&D facility in San Diego and overall SG&A expenses.
- Type
- restructuring
- Charge
- Streamlined Operational Expenditures including closure of the Company's R&D facility in San Diego, reductions in SG&A expenses, and savings related to a more pr
- Affected area
- R&D facility in San Diego and overall SG&A expenses
Exact text from the filing
Streamlined Operational Expenditures: Includes reductions in overall selling, general and administrative (SG&A) expenses, the closure of the Company’s R&D facility in San Diego, as well as savings related to a more prioritized R&D strategy.
View on SEC.gov